Medical devices, healthcare technology and the business of care
PMA approval · P220013

TactiFlex Ablation Catheter, Sensor Enabled, TactiSys Quartz Equipment, TactiSys Quartz, TactiFlex Radiofrequency C

ABBOTT MEDICAL · Decision date May 18, 2023

FDA DECISIONP220013

What did the FDA approve?

FDA records P220013 as an original PMA application. The recorded decision is approval, dated May 18, 2023.

FDA approval order statement

Approval for the TactiFle Ablation Catheter, Sensor Enabled. This device is indicated for use in cardiac electrophysiological mapping and for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation and concomitant atrial flutter, when used in conjunction with a compatible RF generator and three-dimensional mapping system.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
May 18, 2023

FDA source record

Regulatory record facts

Identifier
P220013
Regulatory pathway
Premarket approval application
Product code
OAE
Decision code
APPR
Decision date
May 18, 2023
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation.

Product code
OAE
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P220013 received

    Application receipt date recorded by FDA.

  2. P220013 · FDA decision

    APPR

  3. P220013/S028 · Related supplement

    TactiFlex Duo Ablation Catheter, Sensor Enabled (A-TFDM-D, A-TFDM-F, A-TFDM-J, A-TFDM-DD, A-TFDM-DF, A-TFDM-FF, A-TFDM

  4. P220013/S034 · Related supplement

    TactiFlex Ablation Catheter, Sensor Enabled

Timeline entries are records held by MedtechLedger for P220013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220013

Product / regulatory recordCompanyPathwayDecision dateSource
ABBOTT MEDICALPMA supplementSep 4, 2026FDA
ABBOTT MEDICALPMA supplementSep 22, 2026FDA

Explore the linked device profile

Other records with product code OAE

Product / regulatory recordCompanyPathwayDecision dateSource
STOP Persistent AFP100010/S154
Medtronic Cryocath, LPPMA supplementSep 25, 2026FDA
Biosense Webster, Inc.PMA supplementSep 15, 2026FDA
QDOT MICRO SystemP210027/S018
Biosense Webster, Inc.PMA supplementSep 10, 2026FDA
Biosense Webster, Inc.PMA approvalNov 23, 2022FDA
Medtronic Cryocath, LPPMA approvalDec 17, 2010FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
5050 Nathan Ln. N., Plymouth, MN, 55442

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records